evenfolio

Healthcare · NSE: SENORES

Senores Pharmaceuticals

Q2 FY27 earnings and concall highlights

Price as of 16 Nov 2026
1,147.80−2.28%

Q2 FY27 earnings call · Guided by management

Call held 29 Oct 2026 · Read the filing on NSEFiling

30–40​%Revenue growth · FY27Shah · p. 5
10​%Emerging market margin · Emerging markets · H1 FY27Shah · Q&A · p. 15
10​productsAmerisyn product launches · Amerisyn · next two quartersShah · Q&A · p. 8
₹100​CrApnar revenue · Apnar · FY27Shah · Q&A · p. 9
M.Cap
₹5,286Cr
P/E
38.2×
1Y return
+47.08%
From 52W high
−28.2%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue192162+18.9%180+6.7%
EBITDA5850+16.5%54+7.3%
EBITDA margin30.0%30.6%-63 bps29.8%+15 bps
PBTProfit before tax4841+17.1%39+20.6%
Net profit3932+22.0%31+28.6%
EPS (₹)8.826.54+34.9%6.60+33.6%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

Guidance

Revenue growth · FY2730-40%FY27 revenue growth guidance of 30% to 40% kept
Revenue growth · FY28-FY3025%Annual growth of around 25% expected over 2 to 3 years after FY27
Revenue growth · FY28-FY2925-30%Chairman says about 25% to 30% growth guided to be maintained
Revenue · Apnar · FY27Rs 100 CrApnar expected to contribute about Rs 100 crore-plus revenue this year
Revenue · India branded generics · FY27Rs 50-60 CrIndia branded generics revenue expected at Rs 50-60 crore this year
EBITDA margin · FY2730%FY27 EBITDA margin expected at 30%, maybe a little higher
EBITDA margin · Regulated markets · long term1-2 percentage pointsReason given: new product launches
Profit growth · FY2750-60%FY27 PAT growth guidance of 50% to 60% kept

Regulated markets: All 64 approved ANDAs expected to be commercialised in six to eight quarters

Swapnil Shah · Promoter and Managing Director · Q&A · p. 17
“So, as we move forward, more and more products coming in next few quarters, six, eight quarters that we've stated, we expect our 64 of 64 will be commercialized as we speak from the portfolio that we have.”

Regulated markets: 84 ANDAs expected to be commercialised over the next three to four years

Swapnil Shah · Promoter and Managing Director · Q&A · p. 17
“So, if hindsight if you think about it, in next three to four years, we have 41 plus 43, 84 ANDAs that are going to be commercialized in next two to three to four years timeframe.”

Zoraya: 14 ANDAs planned to launch under Zoraya in FY27

Swapnil Shah · Promoter and Managing Director · Q&A · p. 18
“But high level that I can say, we have 14 ANDAs that are going to be that are planned to launch under Zoraya, in as Zoraya becomes live.”

Emerging markets: Full-year emerging market margin expected at lower to mid-teens

Swapnil Shah · Promoter and Managing Director · Q&A · p. 7
“So full year we expect we'll be about mid-teens to low lower-teens of margin on emerging markets”

MD confirms the stated FY27 guidance is maintained and expects to achieve it

Swapnil Shah · Promoter and Managing Director · Q&A · p. 6
“Yes. So if you can see, we at H1 FY26 to H1 FY27, our EBITDA is already grown by 58%. So, we expect with Zoraya, Amerisyn coming in and the further launch pipelines, very visible pipeline that we have today for next quarter, I mean coming quarter and a quarter after, January we expect to achieve our guidance that we stated.”

More figures from the call

Company · Guidance
50​%PAT growth · FY27
“So yes, overall, I think the bottom-line growth this year should be more than the top-line growth. It's just an indicative statement of about 50-odd percent is what Swapnil has said based on our internal calculations.”
Sanjay Majmudar · Chairman · Q&Ap. 10
Controlled substances · Guidance
4–5​productsControlled substance launches · FY27
“We are expected to launch about four to five controlled substance within this year before March 31st, 2027.”
Swapnil Shah · Promoter and Managing Director · Q&Ap. 7
Regulated markets · Guidance
3–4​ANDAsNew ANDA approvals · Q3 FY27
“We've launched couple of products in current quarter and this quarter also, Q3 FY27, we expect three to four new ANDA approvals to come in and corresponding supplement ANDAs, so sANDA and the strengths that we talk about, it's that's about 12 to 15 sANDAs are expected to approve on our portfolio.”
Swapnil Shah · Promoter and Managing Director · Q&Ap. 6

In short

  1. 01FY27 guidance kept at 30% to 40% revenue growth and 50% to 60% PAT growth.
  2. 02Around 25% annual growth expected for 2 to 3 years after FY27.
  3. 03FY27 EBITDA margin aimed at 30% or a little higher.
  4. 04Q2 FY27 revenue was Rs 192 crore, up 25%; EBITDA Rs 58 crore at 30% margin.
  5. 05Amerisyn and Zoraya expected to start sales this quarter; their Rs 4 crore Q2 cost had no revenue.
  6. 06Apnar plant to have four lines by March 2027 and about Rs 100 crore revenue in FY27.
  7. 07Emerging market margin fell in Q2 on beta-lactam orders; full year seen at lower to mid-teens.

Capex

H1 FY27 capex about Rs 46 crore

Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
“Our capex for H1 of FY27 is approximately INR46 crores.”

Capacity

Apnar: Apnar to have four commercial lines by March 31, 2027; third line being installed

4​lines
Swapnil Shah · Promoter and Managing Director · Q&A · p. 6
“From the lines perspective, as I said, we have plans to have total four commercial lines at Apnar facility by March 31st, 2027. Two lines were already there. Third line, as we speak are getting installed and the fourth will be done before March 2027.”

Apnar: Apnar capacity to be about 1.2 billion units with four lines

Swapnil Shah · Promoter and Managing Director · Q&A · p. 6
“So, with that, we'll have about four commercial lines with a total production capacity of about 1.2 billion units from Apnar facility”

Apnar: Apnar running at 90% to 100% capacity, mostly for validation

Swapnil Shah · Promoter and Managing Director · Q&A · p. 6
“So Apnar, we are operating at almost 90% to 100% of the capacity, but large part of our capacity is all being used for validation for our product launches.”

Apnar: Over 50% of Apnar work is validation; full use not yet in revenue

Swapnil Shah · Promoter and Managing Director · Q&A · p. 6
“But the complete utilization is not generating in the revenue as yet. Since there's lot of validation work, more than 50% validation work is going on.”

Emerging markets: Pre-filled syringe line installed to support GLP-1 and other products

Swapnil Shah · Promoter and Managing Director · p. 4
“On emerging markets, we with installation of pre-filled syringe line, we will support our growth for GLP-1 and other products.”

Segments

Emerging markets: Emerging market margin expected back to Q4 FY26 level from current quarter

Swapnil Shah · Promoter and Managing Director · Q&A · p. 7
“So, we because of that, that's a little bit of margin decline on the emerging market that you have seen in this quarter, but from current quarter onwards again you will it will go back to what we were in Q4 FY26.”

Emerging markets: Emerging market revenue grew about 21% in Q2 and 25% in H1 FY27

Swapnil Shah · Promoter and Managing Director · p. 4
“Moving to emerging market business, revenue grew by approximately 21% in Q2 and 25% in H1 FY27.”

Regulated markets: Regulated market grew 28% in Q2 and 34% in H1 FY27

Swapnil Shah · Promoter and Managing Director · p. 3
“Our regulated market business continued to deliver strong growth, registering Y-o-Y growth of 28% in Q2 and 34% in H1 FY27, driven by portfolio expansion and differentiated sales and distribution channels.”

CDMO CMO: Three CDMO/CMO ANDAs covering 12 strengths commercialised

3​ANDAs
Swapnil Shah · Promoter and Managing Director · p. 3
“On CMO CDMO front, we have commercialized three ANDAs covering 12 strengths.”

Meaningful acceleration expected in H2 FY27

Swapnil Shah · Promoter and Managing Director · p. 3
“Supported by established marketing partnerships, launch readiness and calibrated manufacturing capacities, we expect a meaningful acceleration in H2 FY27.”

Margins and costs

Emerging markets: Emerging market margin fell in Q2 due to large beta-lactam orders

Swapnil Shah · Promoter and Managing Director · Q&A · p. 7
“So, margins have slightly decreased on the emerging market in this quarter because there have been few large orders of beta-lactam products.”

No margin dip expected as subsidiaries go live

Swapnil Shah · Promoter and Managing Director · Q&A · p. 8
“But do we expect any margin dip? The answer is no, but we will see, we'll continue to monitor and see how the margins progress on because of those two subsidiaries coming live.”

Amerisyn, Zoraya: Subsidiary costs not expected to rise from Rs 4 crore to Rs 20 crore

Swapnil Shah · Promoter and Managing Director · Q&A · p. 13
“Yes, but as I said, you know, going forward, do I do we expect that INR4 crores to become INR20 crores? The answer is no, right?”

Regulated markets: Regulated market margin not expected to go down

Swapnil Shah · Promoter and Managing Director · Q&A · p. 16
“Do we expect it to go down? The answer is no, if that is the question that you'll be asking.”

Operating leverage expected to improve margins as revenue scales

Swapnil Shah · Promoter and Managing Director · p. 4
“As revenues scale up, we expect to benefit from operating leverage and a corresponding improvement in our margin profile.”

Debt and working capital

Operating cash flow of Rs 38 crore in H1 FY27

Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
“On the balance sheet front, we have continued to make steady progress in improving cash generation from operations, with operating cash flow reaching INR38 crores in H1 of financial year 2027.”

Working capital days and receivable days improved

Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
“We have also strengthened our focus on working capital efficiency with a significant improvement in working capital days and the receivable days.”

Unbilled revenue due beyond one year is 8% to 9% of the total

Deval Shah · Whole Time Director and Chief Financial Officer · Q&A · p. 12
“It will not be more than 10%. It will be 8% or 9% of the total.”

Unbilled revenue rose as big products shipped in September

Deval Shah · Whole Time Director and Chief Financial Officer · Q&A · p. 12
“And hence it has added to my accrued income because that those will be sold start the distributor will start selling it in this quarter.”

Acquisitions and new business

Regulated markets: Three sANDAs commercialised; new ANDA approved this quarter to launch in Q3

Swapnil Shah · Promoter and Managing Director · p. 3
“Out of this new approvals, we have commercialized three sANDA and the new ANDA where we got approval this quarter will be launched in FY Q3 2026.”

Amerisyn, Zoraya: Amerisyn and Zoraya expected to start contributing from H2 FY27

Swapnil Shah · Promoter and Managing Director · p. 4
“Over and above this, Amerisyn and Zoraya are expected to start contributing from H2 FY27, providing an additional growth driver with significant scale-up potential over the coming years.”

Amerisyn, Zoraya: More meaningful ramp-up of new ventures expected from FY28

Swapnil Shah · Promoter and Managing Director · p. 4
“With these ventures are expected to begin contributing in H2 FY27, a more meaningful ramp- up is anticipated from FY28 onwards.”

Amerisyn: Amerisyn business expected to start within 10 to 15 days

Swapnil Shah · Promoter and Managing Director · Q&A · p. 8
“So Amerisyn we expect business to commence any moment now, maybe this week we don't know, but within next 10 to 15 days.”

Zoraya: Zoraya about a month to 45 days away; both aimed to start this quarter

Swapnil Shah · Promoter and Managing Director · Q&A · p. 8
“Zoraya maybe another month away, I would say worst case about 45 days from today. But we expect both to commercialize within this quarter that's the goal.”

Management

Talati & Talati appointed as joint auditor

Sanjay Majmudar · Chairman · Q&A · p. 11
“They are associated with very large companies and after evaluating various options, we felt it's a good choice to have a bigger and more reputed firm as a joint auditor”

One-offs

Amerisyn, Zoraya: Q2 and H1 include Zoraya and Amerisyn setup costs with no revenue

Swapnil Shah · Promoter and Managing Director · p. 4
“It is important to note that Q2 and H1 performance includes the initial setup and operating costs for Zoraya and Amerisyn, which were recognized in the P&L without any corresponding revenue contribution.”

Amerisyn, Zoraya: About Rs 4 crore of Zoraya and Amerisyn expenses this quarter

Swapnil Shah · Promoter and Managing Director · Q&A · p. 13
“So, we have incurred about INR4 crores of expenses pertaining to Zoraya and Amerisyn this quarter.”

Risks

Apnar: Apnar FDA inspection concluded with one minor procedural 483

Swapnil Shah · Promoter and Managing Director · p. 4
“As everybody knows, recently we concluded a successful FDA inspection at our Apnar facility with one minor procedural 483 that was received.”

Regulated markets: Acquired ANDAs take 3 to 12 months to move to own facility

Swapnil Shah · Promoter and Managing Director · Q&A · p. 17
“So that's a time lag of 3 to 12 months, depending upon what regulatory pathway you file the products in, right?”

Regulated markets: Launches to be judged over 6 to 12 months; many steps outside company control

Sanjay Majmudar · Chairman · Q&A · p. 17
“And it can't happen at, you know, divide by the number of quarters. It has to be looked at on a more broader time frame of maybe 6 to 12 months, because many things are not under our control.”

Other

Q2 FY27 revenue from operations Rs 192 crore, up 25% year on year

Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
“Starting with the quarterly performance, the consolidated revenue from operations for Q2 FY27 stood at INR192 crores, which as Swapnil said is the highest for us, reflecting a very healthy growth of 25% Y-o-Y.”

Q2 EBITDA Rs 58 crore, up 38%; EBITDA margin 30%, up 290 bps

Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
“Consolidated EBITDA for Q2 2027 stood at INR58 crores, growing by 38% Y-o-Y and EBITDA margin stood at 30%, which improved by 290 bps year-on-year.”

Q2 PAT about Rs 36.6 crore, up 22% year on year

Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
“Profit after tax for the quarter grew by 22% Y-o-Y and came to around INR36.6 crores.”

H1 FY27 revenue Rs 372.5 crore, up 30%

Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
“Coming to the half-yearly performance, consolidated revenue for H1 grew strongly by 30% Y-o-Y and came to INR372.5 crores.”

H1 EBITDA Rs 111 crore, up 58%; margin almost 30%, up about 530 bps

Deval Shah · Whole Time Director and Chief Financial Officer · p. 5
“Consolidated EBITDA for H1 stood at INR111 crores, showing a robust growth of 58% Y-o-Y and EBITDA margin stood at almost 30% in H1 FY27, reflecting a strong improvement of around 530 bps Y-o-Y.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools